Chlorphentermine

Summary

Chlorphentermine (CHEMBL1201269) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 183.68 Da · C10H14ClN

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201269
Name	Chlorphentermine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10007
Molecular formula	C10H14ClN
Molecular weight	183.68
InChIKey	ZCKAMNXUHHNZLN-UHFFFAOYSA-N

SMILES: CC(C)(CC1=CC=C(C=C1)Cl)N

IUPAC name: 1-(4-chlorophenyl)-2-methylpropan-2-amine

Also known as: Chlorphentermine, Clorfentermina, chlorphentermine, SID29216103, CHLORPHENTERMINE

Parent form; salt/anhydrous children: CHEMBL1200595

Patent coverage: 946 distinct patent families (3,921 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Neuronal acetylcholine receptor subunit alpha-4, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Histamine H1 receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 8 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	5.52	AC50	2997	nM	CHEMBL_ACT_25164014
SLC6A4	5.34	AC50	4566	nM	CHEMBL_ACT_25149982
SLC6A3	5.12	AC50	7589	nM	CHEMBL_ACT_25123590
HTR2A	5.04	AC50	9060	nM	CHEMBL_ACT_25173487
CHRNA4	5	AC50	10000	nM	CHEMBL_ACT_25125744

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).